MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its Annual Financial Results 2016 on March 9, 2017 at 7:00 a.m. CET.
The Management team of MorphoSys AG will host a conference call and webcast to present MorphoSys’s Annual Financial Results 2016 and provide an outlook for 2017.
Date: Thursday, March 9, 2017
Time: 2:00 p.m. CET (1:00 p.m. GMT, 8:00 a.m. EST)
Dial-in numbers (listen only):
Germany: +49 89 2444 32975
United Kingdom: +44 20 3003 2666
USA: +1 202 204 1514
Company participants in the call will be:
Dr. Simon Moroney, Chief Executive Officer
Jens Holstein, Chief Financial Officer
Dr. Malte Peters, Chief Development Officer
Dr. Marlies Sproll, Chief Scientific Officer
Participants are kindly requested to dial in up to 10 minutes before the call to ensure a secure line and a prompt start. The presentation slides and webcast link will be available at the Company’s website at www.morphosys.com/conference-calls
A slide-synchronized audio replay of the conference will also be available at the corporate website following the live event.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer’s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®, 100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are registered trademarks of the MorphoSys Group.
